Given that our data identify a hypoxia-HIF2α-PLOD2 axis driving DCLK1-L activation in ccRCC, we speculated that hypoxic ccRCC patients with high PLOD2 expression may derive therapeutic benefits from DCLK1-targeted intervention. Here, DCLK1 is linked to nonpapillary renal cell carcinoma.